Bonnie Bermas

Jul 1, 2024 | jitc.bmj.com | David E. Gerber |Bonnie Bermas |Alexa Meara

Immune related adverse event - irAEImmune Checkpoint InhibitorSurvivorshipMore than a decade into the remarkable era of cancer immunotherapy, we are facing major challenges with the toxicities of the revolutionary immune checkpoint inhibitor (ICI) therapies. While ICIs have substantially improved survival rates for melanoma and lung cancer among other malignancies, we are in the nascent stage of understanding and management of their adverse events.